Food and Drug Administration (FDA) approval was granted after an interim analysis at 12 weeks showed that sacubitril-valsartan led to a 44% reduction in N-terminal probrain natriuretic peptide (NT-proBNP), which was larger than what was observed in the enalapril group (33% reduction) and exceeded the results of the PARADIGM-HF trial. The gene discussed is NPPB; the disease is hydrops fetalis.